Citations

Clear

9383 citation(s) found for "Thomas, PS".

Readability Metrics in Patient Education: Where Do We Innovate?
Jamal, Aleena, Qureshi, Fawad , Qureshi, Fawad , Singh, Som Prabh

Mayo Clinic

Clinics and Practice | November 5, 2024 | Volume: 14 | Issue: 6 | Pages: 2341-2349

10.3390/clinpract14060183 | PMID 39585011 Get It

The increasing use of digital applications in healthcare has led to a greater need for patient education materials. These materials, often in the form of pamphlets, booklets, and handouts, are designed to supplement physician–patient communication and aim to improve patient outcomes. However, the effectiveness of these materials can be hindered by variations in patient health literacy. Readability, a measure of text comprehension, is a key factor influencing how well patients understand these educational materials. While there has been growing interest in readability assessment in medicine, many studies have demonstrated that digital texts do not frequently meet the recommended sixth-to-eighth grade reading level. The purpose of this opinion article is to review readability from the perspective of studies in pediatric medicine, internal medicine, preventative medicine, and surgery. This article aims to communicate that while readability is important, it tends to not fully capture the complexity of health literacy or effective patient communication. Moreover, a promising avenue to improve readability may be in generative artificial intelligence, as there are currently limited tools with similar effectiveness.
659 A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors
Maziarz, Richard T, Yuan, Yuan , Krishnamurthy, Anuradha , Isaacs, James , Cairo, Mitchell S. , Cao, Felicia , Advani, Pooja , Locke, Kenneth W., WETZEL, J. M., Klichinsky, Michael , Condamine, Thomas , Sohal, Davendra , Abdou, Yara George , Pohlmann, Paula R. , Maziarz, Richard Thomas , Murthy, Hemant S. , Reiss, Kim A. , He, Aiwu Ruth , Blumenthal, Daniel J. , Locke, Kenneth, Wetzel, Jeanette, Kennedy, Eugene Paul

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A756-A756

10.1136/jitc-2024-sitc2024.0659 Get It

653 Phase I/II clinical trial for radiation and dendritic cell combination immunotherapy in patients with unresectable hepatocellular carcinoma and cholangiocarcinoma
Wu, Chen , Fonkoua, Lionel Aurelien Kankeu , Wang, Panwen , Hallemeier, Christopher L. , Atwell, Thomas D. , Bornschlegl, Svetlana, Martinez, Kodi, McCoy, Gabrielle, Regan, Kevin M., Shao, Zuoyi , Li, Ying , Hallemeier, Christopher Leigh , Tran, Nguyen, Wang, Junwen , Zhang, Henan , Dietz, Allan B. , Dong, Haidong , Park, Sean S. , Yi, Lin , Roberts, Lewis R.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A749-A750

10.1136/jitc-2024-sitc2024.0653 Get It

Predicting Post‐Mortem α‐Synuclein Pathology by the Combined Presence of Probable REM sleep behavior disorder and Hyposmia
Tremblay, Cécilia , Adler, Charles H. , Shill, Holly A. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Choudhury, Parichita , Belden, Christine M. , Lee‐Iannotti, Joyce , Beach, Thomas G. , Mehta, Shyamal, Beach, Thomas G , Adler, C H , Choudhury, Parichita , Driver‐Dunckley, Erika , Shprecher, David , Atri, Alireza , Serrano, Geidy E.

Mayo Clinic

Movement Disorders Clinical Practice | November 5, 2024 | Volume: 12 | Issue: 2 | Pages: 157-165

10.1002/mdc3.14244 | PMID 39499184 Get It

AbstractBackgroundIdiopathic rapid eye movement sleep behavior disorder (RBD) is a strong known predictor of a final clinicopathological diagnosis of a Lewy type α‐synucleinopathy (LTS). Olfactory dysfunction is an early symptom of synucleinopathies and has been repeatedly associated with the presence of post‐mortem LTS.ObjectiveTo assess the combined value of a clinician diagnosis of probable RBD (PRBD) and hyposmia in predicting the post‐mortem presence of LTS in a broader, less‐selected, volunteer elderly population.MethodsWe studied 652 autopsied subjects from the Arizona Study of Aging and Neurodegenerative Disorders, which were evaluated for PRBD, had completed annual movement and cognitive assessments, and had at least one the University of Pennsylvania Smell Identification Test (UPSIT) olfactory test.ResultsHistological evidence of LTS was significantly more frequent in those who had PRBD (112/152: 73.7%) than those without (177/494: 35.8%) (P < 0.001). LTS was more frequent in cases with PRBD and a low UPSIT score (90.8%) compared to cases with PRBD only (73.7%) (P < 0.001) or cases with a low UPSIT score only (69.4%) (P < 0.001). Sensitivity of PRBD diagnosis for predicting LTS was 38.8% and specificity 88.8%, whereas sensitivity of a low UPSIT score was 74.4% and specificity 73.4% (Youden's index = 0.276 for PRBD, 0.478 for UPSIT). When combining both measures, sensitivity was 34.3% and specificity increased to 97.2%.ConclusionPRBD, diagnosed without sleep study confirmation, combined with a reduced olfactory performance is highly specific for predicting post‐mortem presence of LTS. The combination of both measures may provide a cost‐effective means of predicting LTS in a broader community.
Hamstring-to-Quadriceps Strength Ratios in Women Team Sport Athletes: A Systematic Review
Korpinen, Marika M., Trieschock, Devon, Fields, Jennifer B. , Jones, Margaret T. , Jagim, Andrew R. , Almonroeder, Thomas Gus

Mayo Clinic

Strength & Conditioning Journal | November 5, 2024 | Volume: 47 | Issue: 1 | Pages: 95-108

10.1519/ssc.0000000000000867 Get It

ABSTRACT Women experience a higher rate of anterior cruciate ligament (ACL) injuries than men. Muscle imbalance, in particular hamstring-to-quadriceps (H:Q) strength ratio, is considered a risk factor for ACL injury. The purpose of this systematic review was to identify isokinetic H:Q strength ratios in women team sport athletes and determine whether cutoff values, determined from research with predominantly males, of >0.6 for conventional ratio (Hamstring concentric :Quadriceps concentric [CR]) and >1.0 for functional ratio (Hamstring eccentric :Quadriceps concentric [FR]) were met. The CR (0.6) was not met for team ([mean ± SD: 0.56 ± 0.08]), field (0.57 ± 0.08), and court (0.56 ± 0.08) sports. Handball presented the highest (0.58 ± 0.07), and softball presented the lowest CRs (0.47 ± 0.06). The FR (1.0) was not met for team (0.69 ± 0.14), field (0.85 ± 0.14), and court (0.65 ± 0.14) sports. Soccer presented the highest (0.85 ± 0.14) and handball the lowest (0.66 ± 0.13) FRs. When assessing hamstring and quadriceps strength balance, women team sport athletes did not meet CR or FR values, which may contribute to increased ACL injury risk. H:Q ratios below cutoff values may indicate compromised hamstring strength. It is recommended practitioners implement strength exercises aimed to improve H:Q ratios.
What Is Needed to Support Nonurban Urology in the United States? Perspectives From Urologists in Rural and Underresourced Areas
Kieran, Kathleen , Granberg, Candace F. , Deibert, Christopher M., Granberg, Candace, Burnett, Arthur L. “Bud” , Chung, Paul H.

Mayo Clinic

Urology Practice | November 4, 2024 | Volume: 12 | Issue: 2 | Pages: 264-273

10.1097/upj.0000000000000741 | PMID 39495484 Get It

The effect of smoking on functional outcomes and implant survival of anatomical total shoulder arthroplasty
Amador, Isabella E. , Hao, Kévin A. , Buchanan, Timothy R. , Damrow, Derek S., Hones, Keegan M. , Wright, Thomas W. , LaMonica, Tyler J. , Wright, Thomas W , Hao, Kevin A , Hones, Keegan M , Simcox, Trevor G. , Schoch, Bradley S. , Farmer, Kevin W. , King, Joseph J. , Wright, Jonathan O.

Mayo Clinic

The Bone & Joint Journal | November 1, 2024 | Volume: 106-B | Issue: 11 | Pages: 1263-1272

10.1302/0301-620x.106b11.bjj-2024-0202.r1 | PMID 39481428 Get It

AimsWe sought to compare functional outcomes and survival between non-smokers, former smokers, and current smokers who underwent anatomical total shoulder arthroplasty (aTSA) in a large cohort of patients.MethodsA retrospective review of a prospectively collected shoulder arthroplasty database was performed between August 1991 and September 2020 to identify patients who underwent primary aTSA. Patients were excluded for preoperative diagnoses of fracture, infection, or oncological disease. Three cohorts were created based on smoking status: non-smokers, former smokers, and current smokers. Outcome scores (American Shoulder and Elbow Surgeons (ASES), Constant-Murley score, Shoulder Pain and Disability Index (SPADI), Simple Shoulder Test (SST), University of California, Los Angeles activity scale (UCLA)), range of motion (external rotation (ER), forward elevation (FE), internal rotation, abduction), and shoulder strength (ER, FE) evaluated at two- to four-year follow-up were compared between cohorts. Evaluation of revision-free survival was performed using the Kaplan-Meier method to final follow-up.ResultsWe included 428 primary aTSAs with a mean follow-up of 2.4 years (SD 0.6). Our cohort consisted of 251 non-smokers, 138 former smokers who quit a mean 21 years (SD 14) prior to surgery (25 pack-years (SD 22)), and 39 current smokers (23 pack-years (SD 20)). At two- to four-year follow-up, former smokers had less favourable SPADI, SST, and FE strength compared to non-smokers, and current smokers had less favourable SPADI, SST, ASES score, UCLA score, Constant-Murley score, FE, abduction, and ER strength compared to non-smokers. Non-smokers exhibited higher revision-free survival rates at two, five, eight, and ten years postoperatively compared to former smokers and current smokers, who had similar rates.ConclusionOur study suggests that smoking has a negative effect on aTSA functional outcomes that may persist even after quitting.Cite this article: Bone Joint J 2024;106-B(11):1263–1272.
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma
Fléchon, Aude , Morales‐Barrera, Rafael , Powles, Thomas , Alva, Ajjai , Csőszi, Tibor , Loriot, Yohann , Rodríguez‐Vida, Alejo , Géczi, Lajos , Cheng, Susanna Y. , Fradet, Yves , Vulsteke, Christof , Gündüz, Şeyda , Mamtani, Ronac , Pino, Á. Montesa , Gravis, Gwénaëlle , Révész, János, Kostorov, Vladimir, Ma, Junshui , Rajasagi, Mohini, Lunceford, Jared , Imai, Kentaro , Moreno, Blanca Homet , Matsubara, Nobuaki , Özgüroğlu, Mustafa , Csöszi, Tibor , Loriot, Yohann , Rodriguez-Vida, Alejo , Géczi, Lajos , Cheng, Susanna Y , Fradet, Yves , Oudard, Stéphane , Vulsteke, Christof , Gunduz, Seyda , Mamtani, Ronac , Yu, Evan Y , Montesa Pino, Alvaro , Anido, Urbano , Sendur, Mehmet A N , Gravis, Gwenaelle , Kostorov, Vladimir , Huillard, Olivier , Ma, Junshui , Rajasagi, Mohini , Vajdi, Amir , Lunceford, Jared , Cristescu, Razvan , Imai, Kentaro , Homet Moreno, Blanca , Matsubara, Nobuaki , Powles, Thomas , Özgüroğlu, Mustafa , Oudard, Stéphane

Mayo Clinic

Clinical Cancer Research | October 30, 2024 | Volume: 30 | Issue: 23 | Pages: 5353-5364

10.1158/1078-0432.ccr-23-3518 | PMID 39475359 Get It

Abstract Purpose: The three-arm, phase III KEYNOTE-361 study did not meet its dual primary endpoints of progression-free survival (PFS) or overall survival (OS) with first-line pembrolizumab plus chemotherapy versus chemotherapy in advanced urothelial carcinoma. This prespecified exploratory analysis assessed the association of tumor mutational burden (TMB) and PD-L1 combined positive score (CPS) with clinical outcomes. Patients and Methods: TMB and PD-L1 CPS were determined via whole-exome sequencing and PD-L1 IHC 22C3 pharmDx, respectively. The association was evaluated in each treatment arm using logistic regression [objective response rate (ORR)] and Cox proportional hazards regression models (PFS and OS); one-sided (pembrolizumab monotherapy; pembrolizumab plus chemotherapy) and two-sided (chemotherapy) nominal P values were calculated. Significance was prespecified at α = 0.05 without multiplicity adjustment. Efficacy was evaluated by prespecified cutoffs of 175 mutations/exome (TMB) and CPS 10 (PD-L1). Results: Of the 993 treated patients, 820 (82.6%) and 993 (100%) had evaluable TMB and CPS data, respectively. Continuous TMB was positively associated with ORR, PFS, and OS for pembrolizumab monotherapy (one-sided P &lt; 0.001, P &lt; 0.001, and P = 0.007, respectively); PFS and OS for pembrolizumab plus chemotherapy (one-sided P = 0.007 and P = 0.010, respectively); and OS for chemotherapy alone (two-sided P = 0.040). Continuous PD-L1 CPS showed evidence of anticipated association with ORR and PFS for pembrolizumab monotherapy. The subgroup with TMB ≥175 mutations/exome and PD-L1 CPS ≥10 had the highest PFS and OS improvements with pembrolizumab alone or with chemotherapy versus chemotherapy alone. Conclusions: These data suggest that TMB may be predictive of the response to pembrolizumab alone or with chemotherapy in advanced urothelial carcinoma.
Artificial Intelligence/Machine Learning Externally Validated Models for AKI Risk-Classification: A Systematic Review and Meta-Analysis
Braun, Chloe G. , Chen, Jin, Kane‐Gill, Sandra L. , Ninan, Jacob, Neyra, Javier A. , Kane-Gill, Sandra L , Cama-Olivares, Augusto , Takeuchi, Tomonori , Kaiser, Kathryn A. , Ghazi, Lama , Chen, Jin, Forni, Lui G. , Ostermann, Marlies , Shickel, Benjamin

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024mp7992ze Get It

Renal Uric Acid Crystals Trigger Cystogenesis and CKD in Polycystic Kidney Disease
Holznecht, Nickolas J., Strubl, Sebastian , Mueller, Roman-Ulrich, Torres, Jacob A. , Harris, Peter C. , Weimbs, Thomas

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024xw9pwnwn Get It